Biotec Pharmacon strengthening market presence for its flagship Woulgan product
Christian Jorgensen, chief executive of Biotec Pharmacon (FRA:B4V), talks Proactive London's Andrew Scott through the firm's two technology platforms - one of them's a unique enzymes platform where they sell to diagnostics and gene therapy companies.
The second platform is focused on BetaGlucens which develops and manufactures immune modulating compounds for the human health sectors. The technology's currently being used in a wound care product called Woulgan.
Quick facts: Biotec Pharmacon
Market Cap: £0.00
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE